<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25397550</article-id><article-id pub-id-type="pmc">4225259</article-id><article-id pub-id-type="publisher-id">19806</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19806</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P274</subject></subj-group></article-categories><title-group><article-title>Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Spagnuolo</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib><contrib contrib-type="author"><name><surname>Galli</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib><contrib contrib-type="author"><name><surname>Bigoloni</surname><given-names>Alba</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib><contrib contrib-type="author"><name><surname>Nozza</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib><contrib contrib-type="author"><name><surname>d'Arminio Monforte</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="AF0002_19806">2</xref></contrib><contrib contrib-type="author"><name><surname>Antinori</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0003_19806">3</xref></contrib><contrib contrib-type="author"><name><surname>Di Biagio</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="AF0004_19806">4</xref></contrib><contrib contrib-type="author"><name><surname>Rusconi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="AF0005_19806">5</xref></contrib><contrib contrib-type="author"><name><surname>Guaraldi</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="AF0006_19806">6</xref></contrib><contrib contrib-type="author"><name><surname>Di Giambenedetto</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="AF0007_19806">7</xref></contrib><contrib contrib-type="author"><name><surname>Lazzarin</surname><given-names>Adriano</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib><contrib contrib-type="author"><name><surname>Castagna</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="AF0001_19806">1</xref></contrib></contrib-group><aff id="AF0001_19806"><label>1</label>Department of Infectious Diseases, IRCCS San Raffaele Hospital, Milan, Italy</aff><aff id="AF0002_19806"><label>2</label>Clinic of Infectious and Tropical Diseases, S Paolo Hospital, University of Milan, Milan, Italy</aff><aff id="AF0003_19806"><label>3</label>Clinical Department, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy</aff><aff id="AF0004_19806"><label>4</label>Division of Infectious Diseases, Azienda Ospedaliera San Martino, Genoa, Italy</aff><aff id="AF0005_19806"><label>5</label>Division of Infectious Diseases, Ospedale Luigi Sacco, University of Milan, Milan, Italy</aff><aff id="AF0006_19806"><label>6</label>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy</aff><aff id="AF0007_19806"><label>7</label>Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19806</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Spagnuolo V et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19806"><title>Introduction</title><p>The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.</p></sec><sec id="st2_19806"><title>Material and Methods</title><p>Multicentre, randomized, open-label, non-inferiority trial (non-inferiority margin &#x02212;10%). Treatment failure (TF) was defined as CVF (two consecutive HIV-RNA &#x0003e;50 cp/mL) or discontinuation for any cause. In the monotherapy arm, patients with CVF re-introduced their previous NRTIs and remained in the study if HIV-RNA &#x0003c;50 copies/mL within 12 weeks of re-intensification.</p></sec><sec id="st3_19806"><title>Results</title><p>101 patients evaluated (<xref ref-type="fig" rid="F0001_19806">Figure 1</xref>): 85% males, 21% HCV-positive, median (IQR) age of 42 (36&#x02013;48) years, baseline CD4+ 576 (447&#x02013;743) cells/&#x000b5;L. In the 96-week analysis (ITT; TF=failure), efficacy was 64% (32/50) in the monotherapy arm and 63% (32/51) in the triple-therapy arm (difference +1.3%, 95% CI &#x02212;17.5&#x02013;20.1). Fourteen patients in monotherapy and two in triple-therapy arm had CVF; median HIV-RNA was 136 (72&#x02013;376) copies/mL. In monotherapy arm, no PI or NRTI associated resistance mutations were observed at CVF. All patients who re-intensified re-suppressed. In monotherapy arm, TF was more frequent in HCV-co-infected patients (64% vs 28%; p=0.041). In the secondary analysis (ITT; re-intensification=success), 82% (41/50) in monotherapy arm and 63% (32/51) in triple-therapy arm were on study at week 96 (difference +19.3%, 95% CI 2.2&#x02013;36.3). SAEs occurred in four (8%) patients in the monotherapy arm (one left basal pneumonia, one acute coronary stenosis, one traumatic lesion, one nephrolithiasis) and two (4%) in the triple therapy arm (one sepsis, one renal failure). Drug-related adverse events (AEs) leading to discontinuation were three (6%) in the monotherapy arm (two AEs occurred in patients after successful re-intensification) and 12 (23.5%) in the triple-therapy (p=0.023).</p></sec><sec id="st4_19806"><title>Conclusions</title><p>Despite the small sample size, the primary 96-week analysis showed that simplification to ATV/r monotherapy showed inferior efficacy to maintaining ATV/r triple-therapy but appeared to be superior when re-intensification was considered success.
</p></sec></abstract></article-meta></front><body><fig id="F0001_19806" position="float"><label>Figure 1</label><caption><p>The MODAT trial: 96-week patients disposition.</p></caption><graphic xlink:href="JIAS-17-19806-g001"/></fig></body></article>